Innovaderm Resarch Inc, Monreal, QC.
J Cutan Med Surg. 2012 Jul-Aug;16(4):257-60. doi: 10.1177/120347541201600407.
Current therapeutic options for extensive alopecia areata (AA) often lead to disappointing results.
To study the efficacy and safety of adalimumab in patients with severe AA.
This was a prospective, open-label, single-center, pilot study. Three subjects of the planned 10 were enrolled and received two weekly subcutaneous (SC) loading doses of adalimumab 80 mg followed by 40 mg SC every week for 6 months. Patients were evaluated for efficacy and safety on a monthly basis.
Enrolment in this trial was stopped following publication of studies showing no improvement in patients with AA treated with tumor necrosis factor α antagonists. One patient had a favorable response to adalimumab, whereas the two other patients had no benefit from the therapy. Adalimumab was well tolerated by patients with AA.
Adalimumab was well tolerated in patients with AA but did not induce clinically significant hair regrowth.
目前治疗广泛性斑秃（AA）的方法往往效果不佳。
研究阿达木单抗治疗严重 AA 的疗效和安全性。
这是一项前瞻性、开放标签、单中心、初步研究。原计划纳入 10 例患者，其中 3 例入组并接受了两次每周皮下（SC）注射阿达木单抗 80mg 的负荷剂量，随后每周 SC 注射 40mg，持续 6 个月。每月对患者进行疗效和安全性评估。
在 TNF-α拮抗剂治疗 AA 患者无改善的研究发表后，该试验停止了入组。1 例患者对阿达木单抗有良好的反应，而另外 2 例患者则没有从治疗中获益。阿达木单抗在 AA 患者中耐受性良好。
阿达木单抗在 AA 患者中耐受性良好，但不会引起临床显著的毛发生长。
